

**NOTICE UNDER SECTION 708A(9)(c) OF THE CORPORATIONS ACT**

On 27 May 2025, Invion Limited (ASX: **IVX**) ("**Invion**" or the "**Company**") issued a cleansing notice ("Notice") under section 708A(5)(e) of the Corporations Act 2001 (Cth) ("Corporations Act") in respect of the issue of 7,250,269 fully paid ordinary shares ("Shares") at an issue price of \$0.14 per Share. The Shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act on 26 May 2025.

At the time the Notice was lodged, the Company considered that the Notice included all relevant 'excluded information' of the nature referred to in sections 708A(7) and (8) of the Corporations Act that was required to be set out in the Notice pursuant to section 708A(6)(e) of the Corporations Act. The Company was subsequently advised that at the time the Notice was lodged, the Company was likely in possession of other additional information to which Listing Rule 3.1A would have excluded from disclosure under Listing Rule 3.1, and meeting the definition of 'excluded information'.

Out of an abundance of caution, the Company makes this announcement pursuant to and in accordance with section 708A(9)(c) of the Corporations Act for the purposes of correcting the Notice, which may be considered to be defective.

At the time the Notice was lodged, the Company was in the process of verifying the data relating to the efficacy of the application and use of INV043, specifically early indications of patients responding positively to the treatment with an observable reduction in the NMSC lesion size after a single treatment cycle at 15- and 30- days post treatment, while on average, untreated patient-matched lesions increased slightly in diameter over the same corresponding periods post treatment. The Company subsequently finalised its verification of this information and released an announcement to ASX on 29 May 2025.

The non-compliance relates to an administrative oversight.

This announcement has been authorised by Invion's Board of Directors.

---

**Sign up at Invion's Investor Hub to receive regular updates, provide feedback and participate in discussions:** <https://investors.inviongroup.com/>

**Investor and Media enquiries:**

Thian Chew (Chairman & CEO)  
T: +61 3 9692 7222  
E: [investor@inviongroup.com](mailto:investor@inviongroup.com)

Brendon Lau (Investor & Media Relations)  
M: +61 409 341 613  
E: [brendon.lau@inviongroup.com](mailto:brendon.lau@inviongroup.com)

## **ASX ANNOUNCEMENT**

### **About Invion**

Invion is a life-science company that is leading the global research and development of the Photosoft™ technology for the treatment of a range of cancers, atherosclerosis and infectious diseases. Invion holds the exclusive Australia and New Zealand license rights and exclusive distribution rights to Hong Kong and the rest of Asia Pacific, excluding China, Macau, Taiwan and Japan, to the Photosoft technology for all cancer indications. It also holds the exclusive rights to the technology in Asia and Oceania, excluding China, Hong Kong, Taiwan, Macau, the Middle East and Russia for atherosclerosis and infectious diseases, and subsequently acquired the rights to the United States, Canada and Hong Kong for infectious diseases. Research and clinical cancer trials are funded by the technology licensor, RMW Cho Group Limited. Invion is listed on the ASX (ASX: IVX).

### **About Photodynamic Therapy (PDT)**

Invion is developing Photosoft™ technology as a novel next generation Photodynamic Therapy (PDT). PDT uses non-toxic photosensitisers and light to selectively kill cancer cells and promote an anti-cancer immune response. Less invasive than surgery and with minimal side effects, PDT offers an alternative treatment option aimed at achieving complete tumour regression and long-lasting remission. PDT has also demonstrated broad-spectrum activity across multiple infectious diseases, including bacteria, fungi and viruses. Photosoft has the potential to address the global challenge of antibiotic-resistant "superbugs".